drugset / Trial / NCT06769659
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.
Timeline
- Start
- 2025-03-11
- Primary completion
- 2026-08-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NPT 2042 | Unknown | 80 mg | Oral |
| Comparator | NPT 2042 | Unknown | 160 mg | Oral |